Analysis SUPN
Supernus's $1 billion merger payout comes with a new debt bill
The old Supernus bank line was unused when it closed. The merged drugmaker now has a fresh loan alongside Indivior’s existing borrowing.
Supernus and Indivior have completed their merger, but the cash payout goes to just one set of former shareholders. Legacy Indivior holders are entitled to a $1 billion special dividend. The combined company has drawn a new $650 million term loan to help fund it, with the rest coming from existing cash.
Research by Ticker Byline shows that the new borrowing follows the closure of an unused bank credit line at legacy Supernus. Its October 26 filing says that facility was terminated six days earlier with no advances, letters of credit or other borrowings outstanding.
One company, different proceeds
The transaction closed on November 2. Former Supernus Pharmaceuticals shareholders received 1.5401 shares in the surviving parent for each old share. Former Indivior shareholders own approximately 56.5% of the combined company, while former Supernus holders own 43.5%, on a fully diluted basis.
The special dividend belongs to the former Indivior group. The combined company’s cash contribution and the new loan help finance that payment even though both groups will share in the combined company’s future performance.
The surviving legal parent was previously Indivior. It has been renamed Supernus, Inc., with trading under the SUPN symbol beginning November 3. The former Supernus Pharmaceuticals is now a subsidiary.
A larger drug business with a new financing burden
The combination brings together 11 marketed products for conditions including opioid use disorder, attention-deficit hyperactivity disorder and Parkinson’s disease. Jack Khattar, formerly chief executive of Supernus Pharmaceuticals, leads the combined company.
Both businesses reported revenue growth in their last standalone quarter. Supernus Pharmaceuticals generated $226.8 million in third-quarter 2026 revenue, up from $192.1 million a year earlier. Indivior reported $356 million, compared with $314 million, led by its SUBLOCADE treatment for opioid use disorder.
The new loan also sits alongside an existing debt history. Indivior had also issued $500 million of debt due in 2031 that can convert into shares. Its closing credit agreement continues to identify those notes.
The two companies’ individual 2026 forecasts stopped applying when the merger closed. Investors now need a combined outlook that shows how the wider product portfolio, integration costs and financing commitments fit together.
Our Supernus company profile keeps the two legacy financial histories separate and records the completed merger, ownership terms and debt developments.